Investments
10Portfolio Exits
7Cormorant Capital Investments
10 Investments
Cormorant Capital has made 10 investments. Their latest investment was in Freenome as part of their Series F on February 15, 2024.
Cormorant Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
2/15/2024 | Series F | Freenome | $254M | Yes | Andreessen Horowitz, Ark Ventures, ArrowMark Partners, Artis Ventures, Bain Capital Life Sciences, BrightEdge, DCVC, Eventide Asset Management, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, RA Capital Management, Roche, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price, and Undisclosed Investors | 4 |
11/2/2023 | Series B | Terremoto Biosciences | $175M | Yes | EcoR1 Capital, Novo Holdings, OrbiMed, Third Rock Ventures, and Undisclosed Investors | 2 |
4/7/2021 | Series A | Shoreline Biosciences | $43M | Yes | Boxer Capital, BVF Partners, Commodore Capital, Janus Henderson Investors, Kite Pharma, Logos Capital, Stork Capital, and Undisclosed Investors | 4 |
1/9/2021 | Series B | |||||
11/9/2020 | Series D |
Date | 2/15/2024 | 11/2/2023 | 4/7/2021 | 1/9/2021 | 11/9/2020 |
|---|---|---|---|---|---|
Round | Series F | Series B | Series A | Series B | Series D |
Company | Freenome | Terremoto Biosciences | Shoreline Biosciences | ||
Amount | $254M | $175M | $43M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | Andreessen Horowitz, Ark Ventures, ArrowMark Partners, Artis Ventures, Bain Capital Life Sciences, BrightEdge, DCVC, Eventide Asset Management, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, RA Capital Management, Roche, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price, and Undisclosed Investors | EcoR1 Capital, Novo Holdings, OrbiMed, Third Rock Ventures, and Undisclosed Investors | Boxer Capital, BVF Partners, Commodore Capital, Janus Henderson Investors, Kite Pharma, Logos Capital, Stork Capital, and Undisclosed Investors | ||
Sources | 4 | 2 | 4 |
Cormorant Capital Portfolio Exits
7 Portfolio Exits
Cormorant Capital has 7 portfolio exits. Their latest portfolio exit was VISEN Pharmaceuticals on March 21, 2025.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
3/21/2025 | IPO | Public | 2 | ||
Date | 3/21/2025 | ||||
|---|---|---|---|---|---|
Exit | IPO | ||||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 2 |
Loading...